8-K current report · filed Oct 8, 2026

Vir Biotechnology, Inc. (VIR) 8-K Current Report: October 8, 2026

Item 8.01VIR overview

Short answer

Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 8.01 (Other Events). FDA Fast Track designation for VIR-5500 in late-line metastatic castration-resistant prostate cancer.

Vir Biotechnology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA Fast Track designation for VIR-5500 in late-line metastatic castration-resistant prostate cancer
  • Regulatory status may accelerate FDA interactions and development review for Vir’s oncology candidate
  • VIR-5500 co-developed with Astellas under a global strategic collaboration

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vir Biotechnology, Inc. 8-K filings

Get the next VIR 8-K as it lands

Follow VIR for push alerts, or ask the research agent what this filing means.